Meropenem Steriscience

Meropenem, the active ingredient in Meropenem Steriscience, is a carbapenem antibiotic presented as a sterile powder for reconstitution for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, bacterial meningitis, severe pneumonia and sepsis in hospitalized patients.

GNH USA supplies Meropenem Steriscience as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Meropenem is a carbapenem antibiotic used to treat serious bacterial infections across several organ systems. - Complicated intra‑abdominal infections: achieves rapid bacterial eradication and clinical cure in patients with intra‑abdominal sepsis. - Complicated urinary tract infections: provides effective coverage against resistant Gram‑negative and Gram‑positive pathogens causing UTIs. - Bacterial meningitis: penetrates the cerebrospinal fluid to eradicate meningitis‑causing organisms. - Severe pneumonia: delivers high lung tissue concentrations to treat hospital‑acquired and ventilator‑associated pneumonia. - Sepsis: offers broad‑spectrum activity to control systemic infection and reduce mortality.

Meropenem may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset occurring in many patients. - Diarrhea: loose stools that may be self‑limiting. - Rash: skin erythema or pruritus. - Infusion site reactions: pain, erythema or phlebitis at the injection site. - Headache: transient cranial discomfort.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Clostridioides difficile‑associated colitis: severe diarrhea due to intestinal flora disruption. - Anaphylaxis: acute, life‑threatening hypersensitivity reaction. - Neutropenia: marked reduction in neutrophil count. - Elevated liver enzymes: significant hepatic transaminase rise.

When using Meropenem, clinicians should observe several safety precautions to minimize risk. - Renal function monitoring: adjust dose in patients with impaired kidney function. - Hypersensitivity assessment: avoid use in individuals with known carbapenem or β‑lactam allergy. - Neurological status evaluation: use caution in patients with seizure disorders or CNS disease. - Hepatic function monitoring: observe liver enzymes during prolonged therapy. - Concomitant nephrotoxic drugs: monitor for additive kidney toxicity when combined with aminoglycosides or vancomycin. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Valproic acid: meropenem reduces serum valproate levels, increasing seizure risk. - Probenecid: may increase meropenem plasma concentrations, raising toxicity potential.

Moderate Interactions (Monitor Closely): - Aminoglycosides (e.g., gentamicin): combined nephrotoxicity requires renal function monitoring. - Loop diuretics (e.g., furosemide): may enhance ototoxic risk when used with aminoglycosides. - Warfarin: monitor INR as meropenem may alter anticoagulant effect. - NSAIDs: concurrent use may increase risk of renal impairment.